Thomas Griffith, Ph.D.

griffith
Associate Professor
Urology
Office room number: 
3204
MERF
Office phone: 
319-335-7581
FAX: 
319-356-3900
Lab room number: 
3219
MERF
Lab phone: 
319-335-8406
Research

My research is focused on identifying methods of using apoptotic cell death in the treatment of cancer

The research in my laboratory studies the therapeutic potential of apoptotic cell death in the treatment of cancer. The tumor necrosis family member, TRAIL/Apo-2 ligand, is a potent inducer of tumor cell apoptosis, but is non-toxic against normal cell and tissues, suggesting that TRAIL might be administered as an antitumor therapeutic without the side effects seen with other TNF family members, namely TNF and Fas ligand, and traditional chemotherapeutics.

Employment of various gene delivery systems, such as non-replicative viral vectors, is making it possible to administer genes directly into tumors sites in situ. Using this technology, a recombinant, replication-deficient adenoviral vector encoding the full-length TRAIL cDNA (Ad-TRAIL) was developed in the laboratory as a way to induce tumor cell death. Current experiments are investigating the ability of Ad-TRAIL to activate systemic antitumor immunity.

Additional studies are investigating: 1) the role of the innate immune system, specifically neutrophils, in the anti-tumor response activated by Mycobacterium bovis BCG intravesical therapy for bladder cancer; 2) the role of TRAIL in the immune response to influenza infection; and 3) the ability of apoptotic cells to influence the immune response.

Publications: 

PubMed link

Department/Program affiliations: